Implication of K-ras and p53 in colorectal cancer carcinogenesis in Tunisian population cohort
- 243 Downloads
According to the multistep route of genetic alterations in the colorectal adenoma–carcinoma sequence, the complex K-ras/p53 mutation is one of the first alterations to occur and represent an important genetic event in colorectal cancer (CRC). An evaluation of the mutation spectra in K-ras and p53 gene was effected in 167 Tunisian patients with sporadic CRC to determine whether our populations have similar pattern of genetic alteration as in Maghrebin’s population. Mutation patterns of codon 12–13 of K-ras and exon 5–8 of p53 were analyzed by immunohistochemistry and PCR-SSCP and confirmed by sequencing. Mutations in the K-ras gene were detected in 31.13 % and affect the women more than the men (p = 0.008). Immunostaining showed that expression of p21 ras was correlated with the advanced age (p = 0.004), whereas loss of signal was associated with mucinous histotype (p = 0.003). Kaplan–Meier survival curve found that patients with the K-ras mutation had a shorter survival compared with patients without mutation (p = 0.005). Alteration in p53 was seen in 17.4 % of patients and affects three hot spot codons such as 175, 245, and 248. Overexpression of p53 was seen in 34.1 % and correlated with tumor node metastasis (TNM) advanced stage (p = 0.037) and mucinous histotype (p = 0.001). A high concordance between p53 expression and alteration (p < 0.005) was shown. Concomitant mutations in K-ras and p53 gene were detected in only 4 % of tumors. K-ras and p53 undergo separate pathways in colorectal tumorogenesis. Interestingly, mutations in the K-ras gene might be considered a valuable prognostic factor correlated to poor outcome. p53 gene alterations were rather low in our set, and methylation pattern of p53 is required to elucidate the molecular basis of this protein in CRC.
KeywordsK-ras and p53 Immunohistochemistry Sequencing Prognosis Colorectal cancer
The authors thank the Ministry of Health and Scientific Research for the support of this study.
Conflicts of interest
- 4.Akkiprik M, Ataizi-Celikel C, Düşünceli F, et al. Clinical significance of p53, K-ras and DCC gene alterations in the stage I-II colorectal cancers. J Gastrointest Liver Dis. 2007;1:11–7.Google Scholar
- 18.Bond, C. E.,Umapathy,A., Ramsnes, I. et al. (2011) P53mutation is common in microsatellite stable, BRAF mutant colorectal cancers. Int. J. Cancer. 2012;130(7):1567–76.Google Scholar
- 28.Worthley DL, Leggett BA. Colorectal cancer: molecular features and clinical opportunities. Clin Biochem. 2010;31:31–8.Google Scholar
- 40.Thomas E. Rohan1, Shu-Qiu Li2, Robert Hartwick2 and Rita A. Kandel2. (2006) p53 Alterations and protein accumulation in benign breast tissue and breast cancer risk: a cohort study. Cancer Epidemiol Biomarkers Prev. 2006;15(7):1316–23.Google Scholar
- 42.Westra JL, Schaapveld M, Hollema H, de Boer JP, Kraak MM, de Jong D, et al. Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients. J Clin Oncol. 2005;23(24):5635–43.CrossRefPubMedGoogle Scholar
- 43.Georgee T, Eleni K, Joanna GP, et al. p53 and EGFR expression in colorectal cancer: a reappraisal of ‘old’ tissue markers in patients with long follow-up. Anticancer Res. 2009;29:785–92.Google Scholar
- 47.Lun-Xiu Q, Zhao-You T, Zeng-Chen M, et al. p53 immunohistochemical scoring: an independent prognostic marker for patients after hepatocellular carcinoma resection. World J Gastroenterol. 2002;8:459–63.Google Scholar
- 61.Francoise P, Laurent M, Caroline C, et al. Les voies de la carcinogenése colorectale: intérê t et application pour la pathologiste. Ann Pathol. 2002;22:277–88.Google Scholar